Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: Post-hoc analysis of a randomized controlled trial

Journal of Rheumatology

Volumn 38, Issue 6, 2011, Pages 990-996

  Keystone, Edward C ^a   Curtis, Jeffrey R ^b   Fleischmann, Roy M ^c   Furst, Daniel E ^d   Khanna, Dinesh ^d   Smolen, Josef S ^e,f   Mease, Philip J ^g   Schiff, Michael H ^h   Coteur, Geoffroy ⁱ   Davies, Owen ⁱ   Combe, Bernard ^j  

^a UNIVERSITY OF TORONTO   (Canada)

^b The University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f Hietzing Hospital   (Austria)

^g UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

ⁱ UCB PHARMA   (Belgium)

^j LAPEYRONIE HOSPITAL   (France)

more..

Author keywords

American College of Rheumatology response; Certolizumab pegol; Disease activity; Pain; Physical function; Rheumatoid arthritis

Indexed keywords

CERTOLIZUMAB PEGOL; METHOTREXATE; PLACEBO;

ADULT; AMERICAN COLLEGE OF RHEUMATOLOGY 20; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY SCORE 28; DRUG RESPONSE; FEMALE; HUMAN; JOINT RADIOGRAPHY; MAJOR CLINICAL STUDY; MALE; POST HOC ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RHEUMATOID ARTHRITIS; SCORING SYSTEM;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOUBLE-BLIND METHOD; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; LONGITUDINAL STUDIES; MALE; METHOTREXATE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROGNOSIS; TREATMENT OUTCOME;

EID: 79957827196     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.100935     Document Type: Article

References (32)

1. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364:263-9. (Pubitemid 38942816)
2. Goekoop-Ruiterman YP, Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005;52:3381-90. (Pubitemid 41612204)
3. Verstappen SM, Jacobs JW, van der Veen MJ, Heurkens AH, Schenk Y, ter Borg EJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007;66:1443-9. (Pubitemid 350032650)
4. Soubrier M, Puéchal X, Sibilia J, Mariette X, Meyer O, Combe B, et al. Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. Rheumatology 2009;48:1429-34.
5. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999;130:478-86. (Pubitemid 29135800)
6. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45. (Pubitemid 36091645)
7. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weisman MH, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004;50:1051-65. (Pubitemid 38480815)
8. Keystone E, van der Heijde D, Mason D, Landewe R, van Vollenhoven R, Combe B, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008;58:3319-29.
9. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004;50:1400-11. (Pubitemid 38608061)
10. Strand V, Singh JA. Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. Am J Manag Care 2008;14:234-54.
11. Strand V, Keininger DL, Kavanaugh A. Certolizumab pegol (CZP) induces rapid and sustained clinically meaningful improvements in physical function and health-related quality of life (HRQOL) in patients with rheumatoid arthritis (RA): the RAPID 1 and 2 randomised clinical trials (RCTS). Ann Rheum Dis 2008;67:331.
12. Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002;46:1443-50. (Pubitemid 34620189)
13. Fleischmann R, Vencovsky J, van Vollenhoven R, Borenstein D, Box J, Coteur G, et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis 2009;68:805-11.
14. Smolen JS, Landewe R, Mease P, Brzezicki J, Mason D, Luijtens K, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009;68:797-804.
15. Aletaha D, Funovits J, Keystone EC, Smolen JS. Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum 2007;56:3226-35. (Pubitemid 47585417)
16. Güfe A, Kristensen LE, Geborek P. Six and 12 weeks treatment response predicts continuation of tumor necrosis factor blockade in rheumatoid arthritis: an observational cohort study from southern Sweden. J Rheumatol 2009;36:517-21.
17. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
18. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
19. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
20. van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization / International League Against Rheumatism Criteria. Arthritis Rheum 1996;39:34-40.
21. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45. (Pubitemid 10164318)
22. Hewlett S, Hehir M, Kirwan JR. Measuring fatigue in rheumatoid arthritis: a systematic review of scales in use. Arthritis Rheum 2007;57:429-39. (Pubitemid 46682530)
23. Ware JE, Kosinski M, Keller SK. SF-36 Physical and Mental Health Summary Scales: A user's manual. Boston: New England Medical Center, The Health Institute; 1994.
24. Schiff M, Keystone E, Kvien TK, Curtis JR, Emery P, Luijtens K, et al. DAS28(ESR) response at Week 12 is predictive of long-term disease activity in rheumatoid arthritis patients treated with certolizumab pegol. Ann Rheum Dis 2009;68 Suppl 3:543.
25. Ichikawa Y, Saito T, Yamanaka H, Akizuki M, Kondo H, Kobayashi S, et al. Clinical activity after 12 weeks of treatment with nonbiologics in early rheumatoid arthritis may predict articular destruction 2 years later. J Rheumatol 2010;37:723-9.
26. Smolen JS, Han C, van der Heijde DM, Emery P, Bathon JM, Keystone E, et al. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis 2009;68:823-7.
27. Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
28. Lubeck DP. Health-related quality of life measurements and studies in rheumatoid arthritis. Am J Manag Care 2002;8:811-20.
29. Turesson C, Jacobsson LT, Matteson EL. Cardiovascular co-morbidity in rheumatic diseases. Vasc Health Risk Manag 2008;4:605-14.
30. Aletaha D, Funovits J, Breedveld FC, Sharp J, Segurado O, Smolen JS. Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment. Arthritis Rheum 2009;60:1242-9.
31. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762-84. (Pubitemid 351847559)
32. van der Heijde D, Schiff M, Keystone E, Landewe R, Kvien TK, Curtis JR, et al. Probability to achieve low disease activity at 52 weeks in rheumatoid arthritis (RA) patients treated with certolizumab pegol (CZP) depends on time to and level of initial response [abstract]. Arthritis Rheum 2009;60 Suppl:S374.